Acute coronary syndromes, coronary interventions, stroke, and cardiac arrest are more prevalent in patients with rejected or abandoned PCSK9 inhibitor prescriptions compared to those with paid PCSK9 inhibitor prescriptions [81]. This evidence concerns the gene PCSK9 and acute coronary syndrome.